In CRC, the presence of mutant KRAS is associated with downregulation of major histocompatibility class I (MHCI) molecules [66,67], which means that these cells have an impairment to present antigens (Figure 2) and are less prone to be detected by the immune system. Here, KRAS is linked to colorectal carcinoma.